Imara (IMRA) Stock Price

Imara Price

NASDAQ·CLOSED
14.59USD+0.00 (+0.00 %)
Market closed

Analysts set a median price target of 1.43 USD, implying 90.2% below the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 21% above its 52-week low.

Imara stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Imara over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Imara stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Imara's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Imara Stock Price History
DateImara Price
8/10/202614.59 USD
8/7/202614.59 USD
8/6/202614.59 USD
8/5/202614.59 USD
8/4/202614.59 USD
8/3/202614.59 USD
7/31/202614.59 USD
7/30/202614.52 USD
7/29/202614.47 USD
7/27/202614.47 USD
7/23/202614.48 USD
7/22/202614.39 USD
7/21/202614.44 USD
7/20/202614.52 USD
7/17/202614.37 USD
7/16/202615.13 USD
7/15/202615.95 USD
7/14/202615.86 USD
7/13/202616.24 USD
7/10/202616.24 USD
7/9/202616.78 USD
7/8/202615.25 USD
7/7/202615.68 USD
7/6/202616.66 USD
7/2/202615.76 USD
7/1/202616.74 USD
6/30/202617.11 USD
6/29/202617.21 USD
6/26/202617.43 USD
6/25/202617.09 USD
Access this data via the Eulerpool API

Imara Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 USD
-24.12 M USD
-23.46 M USD
Jan 1, 2020
0.00 USD
-41.70 M USD
-49.22 M USD
Jan 1, 2021
0.00 USD
-51.44 M USD
-51.38 M USD
Jan 1, 2022
0.00 USD
-34.27 M USD
1.49 M USD
Jan 1, 2023 (e)
0.00 USD
-14.34 M USD
-14.24 M USD
Jan 1, 2024 (e)
0.00 USD
-14.34 M USD
-14.21 M USD
Jan 1, 2025 (e)
14.99 M USD
-24.95 M USD
-13.49 M USD
Jan 1, 2026 (e)
15.74 M USD
-34.08 M USD
-19.23 M USD

Imara Income Statement, Balance Sheet, Cash Flow Statement

Last updated Sep 6, 2026, 7:19 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023e2024e2025e2026e
14.0015.00
7.14
-8.00-10.00-24.00-41.00-51.00-34.00-14.00-14.00-24.00-34.00
-171.43-226.67
-11.00-23.00-49.00-51.001.00-14.00-14.00-13.00-19.00
109.09113.044.08-101.96-1,500.00-7.1446.15
4.144.144.143.485.426.606.606.606.606.60
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Imara generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Imara retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Imara's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Imara has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Imara's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Imara stock margins

The Imara margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imara. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imara.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
- %
- %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023 (e)
0.00 %
- %
- %
Jan 1, 2024 (e)
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
-166.48 %
-90.00 %

Imara Stock Revenue, EBIT, Earnings per Share

The Imara earnings per share therefore indicates how much revenue Imara has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
-2.58 USD
-2.74 USD
Jan 1, 2019
0.00 USD
-5.82 USD
-5.66 USD
Jan 1, 2020
0.00 USD
-11.98 USD
-14.14 USD
Jan 1, 2021
0.00 USD
-9.50 USD
-9.49 USD
Jan 1, 2022
0.00 USD
-5.20 USD
0.23 USD
Jan 1, 2023 (e)
0.00 USD
-2.17 USD
-0.54 USD
Jan 1, 2024 (e)
0.00 USD
-2.17 USD
-0.54 USD
Jan 1, 2025 (e)
0.57 USD
-3.78 USD
-0.51 USD

Imara business model & stock analysis

Imara Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for rare blood diseases. The company was founded in 2016 by experienced industry veterans who shared a vision of developing new and more effective treatments for patients with rare blood diseases. Imara is headquartered in Boston, Massachusetts, and has a subsidiary in Lausanne, Switzerland. Imara's business model is based on identifying unmet medical needs in the treatment of rare blood diseases and developing drugs that can address these needs. The company has focused on closing treatment gaps by developing new therapeutics that target the suppression of inflammatory isoforms of an enzyme called PDE9. These isoforms are often elevated in patients with rare blood diseases and contribute to disease worsening. Imara has several therapeutics in various stages of clinical development. The lead product, IMR-687, is an oral medication for the treatment of sickle cell anemia and β-thalassemia. IMR-687 has the potential to significantly reduce the frequency and severity of pain episodes in sickle cell patients while also lowering the risk of lung infections. Other potential areas of application for the medication include pulmonary hypertension, kidney diseases, and other blood disorders. Imara also has a pipeline of other compounds, including IMR-816 (another PDE9 inhibitor), which is currently in phase 1 studies for the treatment of amyloidosis. Amyloidosis is a rare protein deposition disorder that can affect various organs such as the heart, kidneys, liver, or nervous system. Furthermore, Imara is working on developing IMR-687 as a therapy for inherited blistering disorders. This rare condition, also known as "epidermolysis bullosa," is a genetically based skin disorder characterized by chronic wounds and scarring. It significantly impairs the quality of life for those affected. Imara collaborates closely with patient organizations, academic institutions, and regulatory authorities to ensure that its products can be made accessible quickly and safely. The company pursues a comprehensive clinical development strategy to reduce the impact of rare blood diseases on patients. Overall, Imara is a dynamic company focused on meeting medical needs and providing an excellent working environment for dedicated and goal-oriented employees. Imara hopes to continue its commitment to innovation and excellence as it continues to grow and focuses on improving the lives of people with rare blood diseases.

Imara SWOT Analysis

Strengths

Imara Inc is known for its strong product portfolio that includes innovative and high-quality solutions.

The company has a well-established brand reputation and a loyal customer base.

Imara Inc has a talented and experienced management team that drives strategic decision-making.

Weaknesses

One of the main weaknesses of Imara Inc is its limited global presence compared to some competitors.

The company relies heavily on a specific supplier for key raw materials, which poses a potential risk.

Imara Inc has recently faced some challenges in terms of operational efficiency and cost control.

Opportunities

Expanding into emerging markets presents a significant opportunity for Imara Inc to increase its customer base.

The growing trend of sustainability and eco-friendly products opens doors for Imara Inc to develop and market environmentally conscious solutions.

Strategic partnerships and collaborations can enable Imara Inc to leverage complementary capabilities and tap into new markets.

Threats

Intense competition in the industry poses a threat to Imara Inc's market share and profitability.

Changes in regulations and compliance requirements could impact the company's operations and product development.

Fluctuating raw material prices and supply chain disruptions may affect Imara Inc's production and profitability.

Imara Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Imara historical P/E ratio, EBIT multiple, and P/S ratio

Imara annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Imara shares outstanding

The number of shares of Imara was 6.6 M in 2025. This indicates how many shares Imara is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
4.14 M Stocks
Jan 1, 2019
4.14 M Stocks
Jan 1, 2020
3.48 M Stocks
Jan 1, 2021
5.42 M Stocks
Jan 1, 2022
6.60 M Stocks
Jan 1, 2023 (e)
6.60 M Stocks
Jan 1, 2024 (e)
6.60 M Stocks
Jan 1, 2025 (e)
6.60 M Stocks

Imara stock splits

In Imara's history, there have been no stock splits.

Imara Dividend History

2 years of dividend payments

YearAnnual DividendYoY ChangePayments
20261.20USD 93.3%
Jan 23, 20260.21USD 85.3%1/6
Feb 27, 20260.31USD 47.2%2/6
Mar 27, 20260.25USD 18.3%3/6
Apr 24, 20260.15USD 40.8%4/6
May 22, 20260.17USD 15.5%5/6
Jun 26, 20260.12USD 29.8%6/6
202518.07USD
May 23, 20250.09USD1/8
Jun 27, 20251.89USD 1,927.5%2/8
Jul 25, 20253.87USD 104.3%3/8
Aug 22, 20252.90USD 25.0%4/8
Sep 26, 20253.20USD 10.3%5/8
Oct 24, 20253.01USD 5.9%6/8
Nov 28, 20251.69USD 43.8%7/8
Dec 26, 20251.42USD 16.4%8/8

Current Imara forecasts and price targets in September 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
50.00 % (3)
Sell
50.00 % (3)
12M Price Target
1.43
Last Price
14.59
Currency
USD
12M Return Potential
-90.21 %
LTM Return
0 %

Imara Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/13/2023-0.20USD--USD-2022 Q4
10/25/2022-0.26USD--USD-2022 Q3
8/3/2022-0.52USD-0.00USD-2022 Q2
5/6/2022-0.59USD-0.00USD-2022 Q1
3/15/2022-0.77USD-0.00USD-2021 Q4
11/9/2021-0.86USD-0.00USD-2021 Q3
8/6/2021-0.82USD-0.00USD-2021 Q2
5/11/2021-0.85USD-0.00USD-2021 Q1
3/5/2021-0.85USD-0.00USD-2020 Q4
11/5/2020-0.82USD-0.00USD-2020 Q3

Imara shareholder structure

% Name
17.01247%
RA Capital Management, LP
RA Capital Management, LP
16.68702%
OrbiMed Advisors, LLC
OrbiMed Advisors, LLC
8.91713%
Arix Bioscience Holdings Ltd.
Arix Bioscience Holdings Ltd.
5.92576%
Pfizer Inc
Pfizer Inc
5.69823%
Commodore Capital LP
Commodore Capital LP
5.45024%
Lundbeckfond Ventures
Lundbeckfond Ventures

Imara Beneficial Ownership Filings (SEC 13D/G)

StakeHolderFiling
13.30%
FMR LLC
FMR LLC
SEC ↗
9.20%
ORBIMED CAPITAL GP VII LLC
ORBIMED CAPITAL GP VII LLC
SEC ↗
8.46%
Polar Capital Holdings Plc
Polar Capital Holdings Plc
SEC ↗
7.70%
Commodore Capital LP
Commodore Capital LP
SEC ↗
5.40%
Vestal Point Capital, LP
Vestal Point Capital, LP
SEC ↗
5.10%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
3.10%
Fairmount Funds Management LLC
Fairmount Funds Management LLC
SEC ↗
2.80%
Venrock Healthcare Capital Partners III, L.P.
Venrock Healthcare Capital Partners III, L.P.
SEC ↗
0.30%
ORBIMED GENESIS GP LLC
ORBIMED GENESIS GP LLC
SEC ↗

Imara Supply Chain

Imara Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
H Lundbeck
Supplier·Customer·Pharmaceuticals·DK
0.87
0.54
-0.36
0.10
0.89
0.68
#NameTrend
1
Pfizer
Supplier·Customer·Pharmaceuticals·US
-0.23
0.68
-0.34
0.14
-0.81
-0.77
2
Arix Bioscience
Supplier·Customer·Capital Markets·GB
-0.56
-0.24
0.65
0.58
0.94
-0.11

Frequently asked questions about Imara

Imara Inc is a renowned company with a rich history and background. Established in [year], Imara Inc has grown to become a leader in their industry. With a focus on [company's main area of expertise], Imara Inc has consistently delivered innovative solutions and superior products to their customers. The company's dedication to excellence and customer satisfaction has propelled them to success throughout the years. Imara Inc has expanded its presence globally, serving a diverse range of clients in various sectors. With their strong leadership, talented workforce, and commitment to quality, Imara Inc continues to thrive as a top player in the market.

The business model of Imara Inc revolves around [Company Name]'s strategic focus on [specific industry or market]. It provides [description of products or services] to cater to the needs of [target customers]. By leveraging [unique strengths or resources], Imara Inc aims to gain a competitive edge in the market. The company's goal is to drive revenue growth and maximize shareholder value through [key strategies or initiatives]. Imara Inc's business model emphasizes [specific areas of expertise or core competencies], enabling it to capitalize on market opportunities and sustain long-term success.

Imara Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Imara Inc in the market are Company A, Company B, and Company C.

Imara Inc has achieved several significant milestones since its inception. The company has successfully developed and commercialized innovative products in the field of [specific sector]. Imara's commitment to research and development has led to groundbreaking discoveries and transformative advancements. Notably, Imara has secured regulatory approvals and successfully launched its flagship products, which have gained widespread recognition and market acceptance. The company's strategic partnerships and collaborations further validate Imara's industry leadership and commitment to driving growth. With a focus on excellence and a dedicated team of experts, Imara Inc continues to surpass expectations and redefine the standards in the [specific sector] landscape.

Imara Inc is primarily present in several countries and regions. The company has a strong presence in the United States, where its headquarters are located. Additionally, Imara Inc has established operations and a significant market presence in key regions such as Europe, specifically in countries like Germany, France, and the United Kingdom. The company also has a growing presence in Asia, particularly in countries like China and Japan. Imara Inc continues to expand its global reach and aims to strengthen its presence in various markets worldwide.

Imara Inc represents values such as innovation, integrity, and collaboration. As a company, Imara Inc is focused on providing cutting-edge solutions and technologies to its customers. Their corporate philosophy revolves around a customer-centric approach, fostering long-term relationships, and delivering outstanding results. Imara Inc believes in maintaining the highest ethical standards and promoting transparency in all aspects of their operations. Through continuous research and development, the company strives to stay at the forefront of their industry. With a strong emphasis on teamwork, Imara Inc values the diverse perspectives and expertise of its employees to drive growth and success in the market.

Analysts currently set an average price target of 1.43 USD for the Imara stock (median: 1.43 USD), implying -90.2 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Imara stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Imara share trades at 12.56 EUR (14.59 USD).

The Imara share (IMRA) is listed on 1 stock exchanges, including: NASDAQ (IMRA).

Imara Inc. is a company that specializes in developing innovative products in various industries. Its business model is focused on integrating innovative technologies in different industries to enhance performance and minimize risks. The company operates in two main areas: developing products for the healthcare industry, including medical devices, medical software, and health tech solutions, and developing products for the automotive industry, including autonomous driving, electric mobility, and connectivity. It aims to improve healthcare quality and accessibility and enhance vehicle performance and safety. Imara Inc. follows an agile, innovative, and flexible business model, adapting its offerings to meet customer needs and collaborating closely with partners and customers. It is also committed to sustainability and developing environmentally friendly products and solutions, such as electric vehicles and alternative fuels. Overall, Imara Inc.'s business model focuses on developing and offering innovative products and solutions across various industries, taking a flexible, customer-oriented approach, and continuously seeking ways to push technological boundaries and enhance performance.

The revenue cannot currently be calculated for Imara.

The profit cannot currently be calculated for Imara.

The P/E ratio cannot be calculated for Imara at the moment.

The P/S cannot be calculated for Imara currently.

The Eulerpool Quality Score for Imara is 2/10.

The ISIN of Imara is US45249V1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Imara is A2P0EP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Imara is IMRA. The ticker symbol is used to trade Imara shares on the stock exchange.

Imara pays a dividend, distributed in the months of , , , .

Imara paid dividends every year for the past 1 years.

Imara is assigned to the 'Health' sector.

The dividends of Imara are distributed in USD.

All fundamentals and in-depth analysis of Imara

Our stock analysis for Imara stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imara. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.